首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

1983169

骨關節炎治療市場：依藥物類別、給藥途徑、疾病類型、通路和地區分類

Osteoarthritis Drugs Market, By Drug Class, By Route of Administration, By Disease Type, By Distribution Channel, By Geography

出版日期: 2026年02月17日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，骨關節炎治療市場規模將達到84.5億美元，2033年將達到177.5億美元。預計從2026年到2033年，該市場將以11.2%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	84.5億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2025-2032 年）複合年成長率	11.20%	預計金額（2033 年）	177.5億美元

骨質疏鬆症是一種全身性疾病，其特徵是骨量減少和骨組織微結構劣化，導致骨骼脆弱，增加髖部、脊椎和腕部骨折的風險。由於其全球高發病率，骨質疏鬆症被認為是一個嚴重的公共衛生問題，會導致身體殘疾和疼痛。骨質疏鬆症的病理生理機轉在於骨吸收和骨形成之間的失衡。在骨質疏鬆症中，骨吸收超過骨形成，造成負平衡，導致骨質淨減少，骨折風險也相應增加，最終導致畸形和慢性疼痛。如果傷害性疼痛持續至少三個月，則被認為是慢性疼痛。

骨形成與骨吸收之間的失衡可能是由以下一個或多個因素造成的：
重塑單元內骨吸收增加。
重塑單元內骨形成減少（不完全連接）。

市場動態

市場主要企業正專注於內部成長策略，例如收購，預計將推動全球骨關節炎治療市場在預測期內的成長。例如，2022年8月15日，投資服務公司Gurnet Point Capital和醫療保健投資公司Patient Square Capital宣布完成對生技公司Radius Health, Inc.的收購。 Radius的旗艦產品TYMLOS（阿伐洛帕肽）於2017年在美國上市，用於治療停經後高骨折風險女性的骨質疏鬆症。此次收購將使該公司能夠在預測期內進一步擴大其在骨關節炎治療市場的佔有率。

然而，使用Ibuprofen和萘普生等非類固醇消炎劑（NSAIDs）治療骨關節炎疼痛可能導致心血管疾病，預計將阻礙市場成長。例如，2018年6月，歐洲抗風濕病聯盟（EULAR）就曾指出，長期使用NSAIDs治療骨關節炎疼痛會帶來心血管疾病風險。

本報告的主要特點

本報告對全球骨關節炎治療市場進行了詳細分析，包括預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球骨關節炎治療市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球骨關節炎治療市場》報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球骨關節炎治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Pfizer, Inc.
Abbott
Eli Lilly and Company
ABIOGEN PHARMA SpA
Horizon Therapeutics plc
Ferring BV
Merck Sharp & Dohme Corp.
Medivir
Bioventus
Sanofi
Regeneron
GlaxoSmithKline Plc.
Johnson & Johnson Private Limited
Bayer AG
Novartis AG
Ferring BV
Pacira Pharmaceuticals, Inc
Zimmer Biomet
OrthogenRx, Inc.
PHARMED LTD

第10章分析師建議

機會
分析師意見
Coherent Opportunity Map (COM)

第11章參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI2580

Osteoarthritis Drugs Market is estimated to be valued at USD 8.45 Bn in 2026 and is expected to reach USD 17.75 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 8.45 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.20%	2033 Value Projection:	USD 17.75 Bn

Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months.

The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors:
Increased bone resorption within a remodeling unit.
Decreased bone formation within a remodeling unit (incomplete coupling)

Market Dynamics

Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius' lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period.

However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.

Key features of the study

This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global osteoarthritis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Analgesics
- Non-steroidal Anti-Inflammatory Drugs
- Corticosteroids
- Hyaluronic Acid
- Phase III Drugs
Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Oral
- Parenteral
- Topical
Disease Type Insights (Revenue, USD Bn, 2026 - 2033)
- Ankle Osteoarthritis
- Hip Osteoarthritis
- Knee Osteoarthritis
- Shoulder Osteoarthritis
- Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- Pfizer, Inc.
- Abbott
- Eli Lilly and Company
- ABIOGEN PHARMA S.p.A
- Horizon Therapeutics plc
- Ferring B.V.
- Merck Sharp & Dohme Corp.
- Medivir
- Bioventus
- Sanofi
- Regeneron
- GlaxoSmithKline Plc.
- Johnson & Johnson Private Limited
- Bayer AG
- Novartis AG
- Ferring B.V.
- Pacira Pharmaceuticals, Inc
- Zimmer Biomet
- OrthogenRx, Inc.
- PHARMED LTD

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Osteoarthritis Drugs Market, By Drug Class
- Global Osteoarthritis Drugs Market, By Route of Administration
- Global Osteoarthritis Drugs Market, By Disease Type
- Global Osteoarthritis Drugs Market, By Distribution Channel
- Global Osteoarthritis Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Osteoarthritis Drugs Market, By Drug Class, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Non-steroidal Anti-Inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Hyaluronic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Phase III Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Osteoarthritis Drugs Market, By Route of Administration, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Osteoarthritis Drugs Market, By Disease Type, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Ankle Osteoarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Hip Osteoarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Knee Osteoarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Shoulder Osteoarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

7. Global Osteoarthritis Drugs Market, By Distribution Channel, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

8. Global Osteoarthritis Drugs Market, By Region, 2020 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abbott
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
ABIOGEN PHARMA S.p.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Horizon Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck Sharp & Dohme Corp.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medivir
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bioventus
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson Private Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pacira Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zimmer Biomet
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
OrthogenRx, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
PHARMED LTD
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies